Section
This review synthesizes recent clinical evidence on the integration of plasma p-tau217 and eMTBR-tau243, highlighting how sequential biomarker testing improves the diagnosis of symptomatic Alzheimer’s disease and predicts longitudinal cogni
Subgroup analysis of the OPTIMAS trial reveals that neither the timing of atrial fibrillation diagnosis nor AF subtype modifies the treatment effect of early versus delayed direct oral anticoagulant initiation in acute ischemic stroke. Pers
A landmark study of 631 participants reveals that normative modeling uncovers substantial individual heterogeneity in brain morphology following traumatic brain injury that conventional group-based analyses miss, with every patient exhibiti
The EDESTROKE trial finds no significant difference in 90-day functional outcomes between early (<6h) and delayed (6-12h) extubation post-thrombectomy, shifting focus toward microvascular and hemodynamic optimization.
This review synthesizes evidence on sex differences in syncope management, highlighting that while men face higher admission rates and adverse events, these disparities are largely driven by baseline clinical risk factors rather than gender
A retrospective cohort study reveals that dementia patients with preferred language other than English are more likely to have documented goals-of-care discussions yet experience significantly higher hospital-based healthcare utilization ne
Recent advances in digital pathology and machine learning reveal that APOE ε4 promotes proteinopathy and modifies dementia thresholds, while multi-modal trajectories suggest distinct pathways for disease progression in Lewy body disease.
The Phase 4 RESOLUTION trial demonstrates that eptinezumab 100 mg IV, combined with standardized patient education, significantly reduces migraine frequency and acute medication reliance in adults with comorbid chronic migraine and medicati
Four men exposed in childhood to cadaveric pituitary-derived human growth hormone developed dementia decades later; one autopsied case showed severe Alzheimer-type pathology, including tauopathy, supporting a transmissible iatrogenic Alzhei
A retrospective study reveals that 24% of patients meeting the latest MS criteria following optic neuritis actually have MOGAD or NMOSD, emphasizing the need for antibody testing to prevent misdiagnosis.
The SECRETO study reveals that infections within the preceding week significantly increase the risk of cryptogenic ischemic stroke in patients aged 18–49, with elevated von Willebrand Factor and Factor VIII levels serving as critical biomar
The Phase 2b PARADIGM trial demonstrates that PrimeC—a novel combination of celecoxib and ciprofloxacin—is safe and significantly slows functional decline in ALS patients over 18 months, offering new hope for multi-target neuroprotective st
Researchers using human stem cell models have discovered that macrophages actively amplify the electrical signals of damaged nerves, driving the spontaneous pain characteristic of neuropathy, offering a new target for non-opioid pain relief
A large-scale prospective study identifies high basal ganglia perivascular space (BGPVS) burden as a significant predictor of both major bleeding and ischemic stroke in patients on antithrombotic regimens, offering a new imaging biomarker f
The Phase 3 TEMPO-3 trial demonstrates that tavapadon, a novel selective D1/D5 agonist, significantly improves daily ‘good-on-time’ and reduces ‘off-time’ in Parkinson’s disease patients with motor fluctuations, pres
A multicenter randomized controlled trial reveals that integrating action observation with virtual reality significantly improves paretic hand dexterity in stroke patients, with benefits persisting six months post-intervention, offering a s
A groundbreaking human iPSC-derived co-culture study reveals that macrophages respond to neuronal injury by adopting a pro-algesic state, directly intensifying spontaneous neuronal firing—a key driver of chronic neuropathic pain and a novel
A large prospective study reveals that a high burden of basal ganglia enlarged perivascular spaces (BGPVSs) significantly increases the risk of both ischemic stroke and major bleeding in patients on antithrombotic therapy, positioning BGPVS
The Phase 3 TEMPO-3 trial demonstrates that tavapadon, a selective D1/D5 agonist, significantly increases ‘good-on-time’ and reduces ‘off-time’ in Parkinson’s patients with motor fluctuations, offering a favorable sa
A landmark study using lesion network mapping reveals that cerebral palsy after neonatal stroke is driven by disruptions in extensive functional networks, including the thalamus and cerebellum, rather than just localized motor cortex damage
